Tag: poly (adp-ribose) polymerase (parp) inhibitors market share

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry In 2025?

The poly (adp-ribose) polymerase (parp) inhibitors market has experienced substantial expansion in recent years. It is projected to expand from $5.58 billion in 2024 to $6.41 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.9%. This historical growth can be linked to factors such as rising healthcare spending, an increasing need for maintenance treatments, the growing application of combination therapies, the emerging focus on personalized medicine approaches, and greater investment in oncology pipelines.

The market for poly (adp-ribose) polymerase (parp) inhibitors is projected to experience substantial expansion in the coming years. By 2029, its valuation is anticipated to reach $11.05 billion, demonstrating a compound annual growth rate (CAGR) of 14.6%. This anticipated growth during the forecast period stems from factors such as the rising incidence of cancer, the wider acceptance of targeted therapies, an expanding elderly demographic, heightened awareness surrounding genetic testing, and increased engagement in clinical trials. Key trends characterizing this period encompass breakthroughs in genomic sequencing technologies, the creation of companion diagnostic instruments, the incorporation of technology into drug development platforms, and the progression of next-generation poly (ADP-ribose) polymerase (PARP) inhibitors.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24662&type=smp

What Are The Top Growth Drivers Impacting The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Outlook?

An increasing incidence of breast cancer is anticipated to drive the expansion of the poly(ADP-ribose) polymerase (PARP) inhibitors market in the future. Breast cancer is a condition where abnormal cells within the breast multiply uncontrollably, potentially forming a tumor and spreading to other body parts. The growing number of breast cancer cases is attributed to lifestyle factors such as obesity, inactivity, and alcohol consumption, which raise estrogen levels and promote tumor development. Poly(ADP-ribose) polymerase (PARP) inhibitors assist breast cancer treatment by specifically targeting cancer cells with DNA repair deficiencies, particularly BRCA mutations. They reduce tumor proliferation by preventing DNA repair, offering a targeted therapy that enhances patient outcomes and lessens damage to healthy cells. For instance, in March 2025, according to Breastcancer.org, a US-based nonprofit organization, breast cancer makes up about 32% of all new cancer diagnoses, with an estimated 316,950 women projected to be diagnosed with invasive breast cancer, including 59,080 cases of non-invasive types, by 2025. Therefore, the rising number of breast cancer cases is fueling the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market.

What Are The Different Segment Classifications Within The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?

The poly (ADP-ribose) polymerase (PARP) inhibitors market covered in this report is segmented –

1) By Drug Type: Niraparib, Olaparib, Rucaparib, Talazoparib, Veliparib, Other Drug Types

2) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Hospital Pharmacies

3) By Application: Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer, Other Applications

4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users

Which Competitive Trends Are Defining The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Structure?

Key companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are concentrating on developing innovative solutions, such as combination therapies, to improve drug effectiveness, lessen side effects, and expand treatment applications beyond oncology. Combination therapies are treatment approaches that utilize two or more therapeutic agents, including drugs, radiation, or biologics, simultaneously to boost overall efficacy and enhance patient outcomes. For example, in June 2023, Merck & Co. Inc., a US-based pharmaceutical company, and AstraZeneca plc, a UK-based pharmaceutical company, gained approval from the U.S. Food and Drug Administration (FDA) for olaparib (Lynparza) in conjunction with abiraterone and prednisone (or prednisolone) for adult patients suffering from breast cancer gene (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC). Olaparib (Lynparza) operates by inhibiting PARP enzymes, which prevents DNA repair in BRCA-mutated cancer cells, leading to cell demise. When combined with abiraterone and prednisone (or prednisolone), it amplifies anti-tumor activity by obstructing androgen production, a critical factor for prostate cancer growth, thereby decelerating disease progression.

Which Key Players Are Driving Competition In The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?

Major companies operating in the poly (ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, GSK plc, Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Genentech Inc., Ono Pharmaceutical Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., BeiGene, EMD Serono, Myriad Genetics, Clovis Oncology Inc., Repare Therapeutics Inc., Karyopharm Therapeutics, Checkpoint Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/poly-adp-ribose-polymerase-parp-inhibitors-global-market-report

How Do Regional Market Performances Compare Within The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry?

North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly (ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24662&type=smp

Browse Through More Reports Similar to the Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market 2025, By The Business Research Company

Proton Pump Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report

Mtor Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mtor-inhibitors-global-market-report

Alpha Glucosidase Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sector?

The market size for poly (adp-ribose) polymerase (parp) inhibitors has experienced significant growth recently. The market expansion is projected to increase from $5.58 billion in 2024 to $6.41 billion in 2025, with a compound annual growth rate (CAGR) of 14.9%. Factors contributing to the historic growth include a rise in healthcare spending, an increased demand for maintenance treatments, a growing trend in using combination therapies, a surge in personalized medicine methods, and an elevation in investment towards the oncology pipeline.

It is anticipated that the poly (adp-ribose) polymerase (parp) inhibitors market will experience substantial growth in the years to come. The market is projected to expand to $11.05 billion by 2029, with a compound annual growth rate (CAGR) of 14.6%. The predicted growth throughout this period could be due to rising cancer rates, an increase in the use of targeted therapies, an expanding elderly population, greater understanding of genetic testing, and boosted clinical trial activity. Noteworthy trends in the forecast period encompass improvements in genomic sequencing technologies, the creation of companion diagnostic tools, the incorporation of technology into drug development platforms, and the formulation of next-generation poly (ADP-ribose) polymerase (PARP) inhibitors.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24662&type=smp

What Forces Are Driving The Growth Of The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?

The poly(ADP-ribose) polymerase (PARP) inhibitors market is anticipated to see a surge due to the increasing incidence of breast cancer. This disease is characterized by the uncontrollable growth of abnormal cells in the breast which can eventually form a tumor and spread across the body. Lifestyle-related factors like obesity, a sedentary lifestyle, and alcohol consumption, which spike estrogen levels and foster tumor growth, are typically the causes of the burgeoning number of breast cancer cases. PARP inhibitors, particularly beneficial for breast cancer patients, are designed to target cancer cells that exhibit DNA repair deficiencies, especially BRCA mutations. By disrupting DNA repair, these inhibitors stall tumor growth, thus serving as a focused therapy that elevates the rate of successful treatments and reduces the damage to healthy cells. For instance, as per the March 2025 data from Breastcancer.org, a nonprofit organization based in the US, it was projected that breast cancer would contribute to 32% of all new cancer diagnoses with an approximate 316,950 women likely to be diagnosed with invasive breast cancer, including 59,080 cases of non-invasive types by 2025. Consequently, the escalating number of breast cancer cases is fuelling the expansion of the poly(ADP-ribose) polymerase (PARP) inhibitors market.

How Is The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry Segmented Across Key Parameters?

The poly (ADP-ribose) polymerase (PARP) inhibitors market covered in this report is segmented –

1) By Drug Type: Niraparib, Olaparib, Rucaparib, Talazoparib, Veliparib, Other Drug Types

2) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Hospital Pharmacies

3) By Application: Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer, Other Applications

4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users

What Notable Trends Are Shaping The Direction Of The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?

Leading firms in the poly(ADP-ribose) polymerase (PARP) inhibitors market are concentrating on developing novel approaches, like combination therapies, to increase the effectiveness of drugs, minimize side effects, and broaden their use beyond cancer treatment. Combination therapies employ more than one type of treatment at the same time, like medication, radiation, or biologics, to increase overall efficiency and improve patient health outcomes. To illustrate, in June 2023, Merck & Co. Inc., an American pharmaceutical company, and AstraZeneca plc, a British pharmaceutical firm, gained the U.S. Food and Drug Administration’s (FDA) approval for the usage of olaparib (Lynparza) in conjunction with abiraterone and prednisone (or prednisolone) for adult patients suffering from breast cancer gene (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC). Olaparib (Lynparza), a PARP inhibitor, blocks DNA repair in BRCA-mutated cancer cells, leading to their death. When it is mixed with abiraterone and prednisone (or prednisolone), its anti-tumor capabilities are enhanced by hampering the production of androgen, a crucial element for prostate cancer’s growth, and this slows the progression of the disease.

Which Companies Currently Dominate The Competitive Landscape In The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry?

Major companies operating in the poly (ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, GSK plc, Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Genentech Inc., Ono Pharmaceutical Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., BeiGene, EMD Serono, Myriad Genetics, Clovis Oncology Inc., Repare Therapeutics Inc., Karyopharm Therapeutics, Checkpoint Therapeutics Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/poly-adp-ribose-polymerase-parp-inhibitors-global-market-report

Which Geographic Regions Are Driving Demand In The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?

North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly (ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24662&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model